Modulators of complement activity
The present disclosure relates to polypeptide modulators of complement activity, including cyclic polypeptide modulators. Included are methods of utilizing such modulators as therapeutics. Also provided are methods of measuring C5 and related complexes using C5 binding agents.
1. A pharmaceutical composition comprising:
R5001; and
at least one pharmaceutically acceptable excipient.
2. The pharmaceutical composition of claim 1 , wherein the at least one pharmaceutically acceptable excipient comprises at least one of sodium chloride and sodium phosphate.
3. The pharmaceutical composition of claim 1 , comprising from about 25 mM to about 100 mM sodium chloride.
4. The pharmaceutical composition of claim 1 , comprising from about 10 mM to about 100 mM sodium phosphate.
5. The pharmaceutical composition of claim 1 , wherein R5001 is present at a concentration of from about 1 mg/mL to about 400 mg/mL.
6. A method of treating hemolysis in a subject, the method comprising administering the pharmaceutical composition of claim 1 to the subject.
7. The method of claim 6 , wherein the subject has been treated previously with an antibody-based therapeutic.
8. The method of claim 7 , wherein the subject is resistant or unresponsive to treatment with the antibody-based therapeutic.
9. The method of claim 7 , wherein the antibody-based therapeutic is eculizumab.
10. The method of claim 6 , wherein the pharmaceutical composition is administered at a dose of from about 0.01 mg/kg to about 10 mg/kg.
11. The method of claim 10 , wherein the pharmaceutical composition is administered at a dose of from about 0.1 mg/kg to about 0.3 mg/kg.
12. The method of claim 6 , wherein the pharmaceutical composition is administered daily for at least two days.
13. The method of claim 12 , wherein the pharmaceutical composition is administered daily for about 12 weeks.
14. The method of claim 12 , wherein the pharmaceutical composition is administered daily for at least 1 year.
15. The method of claim 6 , wherein the pharmaceutical composition is administered subcutaneously or intravenously.
16. A method of inhibiting binding of C5 to alternative pathway C5 convertase comprising contacting C5 with R5001.